Peptides DB
Research-centric peptide and protocol reference hub

Vipivotide record · updated 7h ago

Healing & recoveryGrade A · human clinicalResearch use only
All 27 studiesJump to the evidenceCompare
What is Vipivotide used for?

Research peptide discovered via AI researcher. research peptide

How it works: PSMA-targeted radioligand therapy

Primarily researched for · Healing & recoveryRoute · Intravenous injection

Development stage

where Vipivotide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 65 registered trials. It describes the research record, not a recommendation.

Identity
NameVipivotide
Chain length—
Molecular weight—
Formula—
Structure type—
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026
Pharmacology
MechanismPSMA-targeted radioligand therapy
RouteIntravenous injection
Half-life—
Time to peak—
Durationup to 6 doses every 6 weeks
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 31, 2026. How this works →
Research stats
Total studies27
Human / animal / cellular15 / 0 / 1
Highest trial phasePhase 3
Years covered2021–2026
Latest study5d ago
Publication history
20212026
Research funding
2 NIH projects · $1.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports223
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

27 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.
FindingNot reported in abstract.
review2023Full text read0.70
Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer.
FindingMedian clinical OS was 12.0 months (95% CI, 11.0-13.0) for patients with taxane exposure before Lu-177 PSMA.
Human2026Full text read0.80
Characterization of Adverse Drug Effects for Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess.
Finding17,743 ADR reports analyzed.
review2024Full text read0.80
Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).
FindingCabazitaxel had the highest proportion of serious reports at 86.6% and deaths at 22%.
review2023Full text read0.90
Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.
FindingRP2D for 177Lu-FAP-2286 monotherapy determined to be 9.25 GBq.
Human2023Full text read0.80
Overall Survival with [177Lu]Lu-PSMA-617 Versus [177Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.
FindingMedian OS: [177Lu]Lu-PSMA I&T: 14 mo; [177Lu]Lu-PSMA-617: 15 mo; hazard ratio, 1.18; 95% CI, 0.79-1.78; P = 0.42.
Human2023Full text read0.80
Real-world outcomes of [177Lu]Lu-PSMA-I&T in [18F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.
FindingPSA30 response in 44% of patients.
Human2026Full text read0.80
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.
Finding2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24
Human2026Full text read0.80
Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.
FindingMTD established at 1000 mg/m².
Human2026Full text read0.80
Evaluation of [225Ac]Ac-PSMA-617 vis-a-vis Rechallenge [177Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
FindingPSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.
Human2026Full text read0.80
Lutetium Lu 177 vipivotide tetraxetan: A literature review.
FindingNot reported in abstract.
review2023Full text read0.70
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
FindingCumulative renal absorbed dose ranged from 38.6 to 65.3 Gy.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Vipivotide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Vipivotide is discussed should be drawn from it.